Nanotechnology in the treatment of inflammatory bowel diseases

Treatment of inflammatory bowel diseases (IBD) is only aimed to block or inhibit the pathogenetic steps of the inflammatory cascade. Side effects of systemic therapies, poor targeting of orally administered topical drug and low adherence to prescription represent frequent therapeutic challenges. Rec...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Crohn's and colitis 2014-09, Vol.8 (9), p.903-918
Main Authors: Viscido, Angelo, Capannolo, Annalisa, Latella, Giovanni, Caprilli, Renzo, Frieri, Giuseppe
Format: Article
Language:English
Subjects:
Compliance
Drug delivery
Drug Delivery Systems
Humans
Inflammatory bowel diseases
Inflammatory Bowel Diseases - therapy
Microparticles
Nanoparticles
Nanotechnology - methods
Therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Treatment of inflammatory bowel diseases (IBD) is only aimed to block or inhibit the pathogenetic steps of the inflammatory cascade. Side effects of systemic therapies, poor targeting of orally administered topical drug and low adherence to prescription represent frequent therapeutic challenges. Recent observations suggest that nanotechnology could provide amazing advantage in this field since particles having dimension in the nanometer scale (nanoparticles) can modify pharmacokinetic step of biologic and conventional therapeutic agents with a better delivery of drugs within the intestinal inflammatory cells. The aim of this review was to provide the clinician with an insight into the potential role of nanotechnology in the treatment of IBD. A systematic search (PubMed) for experimental studies on the treatment of intestinal inflammation using nanotechnology for the delivery of drugs. The size of the pharmaceutical formulation is inversely related to specificity for inflammation. Nanoparticles can penetrate epithelial and inflammatory cells resulting in much higher, effective and long-acting concentrations than can be obtained using conventional delivery systems. From a practical point of view, this should lead to improvements in both efficacy and adherence to treatment, providing patients with the prospect of stable and prolonged remissions with reduced drug loadings. Reduced systemic side effects could also be expected.
ISSN:1873-9946
1876-4479
DOI:10.1016/j.crohns.2014.02.024